Form 4: Sangamo Therapeutics Executive Sells Shares to Cover Tax Obligations After RSU Vesting

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Nathalie Dubois-Stringfellow, a senior executive at Sangamo Therapeutics, sold a total of 3,295 shares of common stock to cover tax obligations related to the vesting of restricted stock units (RSUs).
• On November 24, 2024, 1,787 shares were sold at $1.88 per share to cover taxes from an RSU vesting.
• On November 25, 2024, 1,508 shares were sold at $1.94 per share for tax withholding purposes related to another RSU vesting.
• These sales were not discretionary trades but were required to cover tax liabilities associated with the vesting of the RSUs.
• Following these transactions, Dubois-Stringfellow still beneficially owns 841,303 shares of Sangamo Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction related to executive compensation and is common for companies that use stock-based compensation. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• The sale of shares to cover tax obligations upon RSU vesting is a standard practice across publicly traded companies, including those in the biotechnology sector.
• Many companies, such as Gilead Sciences and Biogen, use similar equity compensation plans, and their executives often engage in similar transactions.
• The number of shares sold and the price per share are specific to Sangamo's stock and the executive's compensation package, making direct comparisons difficult without detailed knowledge of other companies' plans.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not represent a change in the executive's confidence in the company.
• The sales are not expected to significantly affect the stock price.

Key Dates

Keywords

Sangamo Therapeutics, RSU, restricted stock units, insider trading, stock sale, tax withholding, executive compensation, SGMO